Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Extended therapy with rituximab reduces incidence of AAV relapse

16 Jun 2020

Long-term therapy with biannual infusions of rituximab over 18 months, compared with standard maintenance therapy, results in a lower incidence of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse, a study has shown.

This randomized controlled trial was carried out in 39 clinical centres in France. The investigators identified 69 patients with granulomatosis with polyangiitis (GPA) and 29 with microscopic polyangiitis (MPA) who achieved complete remission after the first phase of maintenance therapy.

From March 2015 to April 2016, 97 patients (mean age, 63.9 years; 35 percent women) were randomly assigned to receive either rituximab (n=50) or placebo infusion (n=47) every 6 months for 18 months (four infusions).

At month 28, relapse-free survival estimates stood at 96 percent (95 percent confidence interval [CI], 91–100) in the rituximab group and 74 percent (95 percent CI, 63–88) in the placebo group, with an absolute difference of 22 percent (95 percent CI, 9–36) and a hazard ratio of 7.5 (95 percent CI, 1.67–33.7; p=0.008). Major relapse-free survival estimates were 100 percent (95 percent CI, 93–100) vs 87 percent (95 percent CI, 78–97 percent), respectively (p=0.009).

At least one serious adverse event (SAE) was reported in 12 patients (24 percent) in the rituximab group (with nine infectious SAEs occurring among six patients) and in 14 patients (30 percent) in the placebo group (with six infectious SAEs developing among four patients). Of note, none of the patients died in either group.

This study was limited by potential selection bias based on previous rituximab response and tolerance, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.